Altimmune, Inc. shares surged nearly 30% after positive Phase 2 clinical study results for pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Pemvidutide may compete with Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback